Omic Sciences
- About the area
- Strategy
- Affiliated groups
Year after year, the impact of omics on people's health is emerging more and more. The omic sciences encompass the full range of factors that can affect individual health and therefore help to understand how human disease works.
With the aim of developing new treatments and diagnostics, the research and innovation of the I3PT seeks to incorporate omic sciences in a transversal way in order to enable personalized, preventive, predictive and participatory medicine.
Strategic lines of the area
- Knowledge generation and technological development
- Exploitation and integration of omic data
- Translation of omic sciences to clinical practice
- Implementation of precision personalized medicine
- Advanced therapies
Active projects
Identification and validation of early biomarkers of acute COVID-19 to predict evolution (IVETTE).
IP: Jordi Gratacós (A8G2). Funder: The Marathon TV3.
collaborators: Irsicaixa, IRBBarcelona.
Impact: Prediction of the clinical evolution of the COVID-19 patient through a proteomic analysis of the patient admitted to the emergency department. The aim is to identify early those patients with an immune system that does not respond well to infection, to anticipate treatment and improve the evolutionary course of the disease.
Integrated analysis of multi-omic data to establish clinical and molecular profiles predictive of the development of recurrent uveitis in patients with HLA-B27 positive ankylosing spondylitis.
IP: Maria Llop (group A8G2). financier: PI22/01775.
Contributors: LOYALTY
Impact: Ankylosing spondylitis (AS) is a chronic form of arthritis of unknown cause, although it appears to have an important genetic basis. Acute anterior uveitis is the most common extra-articular manifestation of AD and carries a significant personal and social disease burden due to vision loss. This project seeks to discover biomarkers using bioinformatics tools that allow an early diagnosis to establish personalized treatments that avoid complications in this uncommon disease.
Theranostics in Vascular Anomalies: Deep Whole Exome Sequencing as a tool for new targeted therapies.
IP: Víctor M Martínez (group A5G3). Funder: Pending resolution.
Contributors: La Paz University Hospital Research Institute.
Impact: The project aims to develop a theranostic approach to boost personalized medicine in vascular anomalies. It develops a methodology for whole-exome sequencing capable of detecting variants in low somatic mosaicism, transforming the detection of postzygotic variants. It will help improve molecular diagnostics, identify molecular pathways involved, discover new genes involved, new uses for existing drugs and develop new targeted therapies for vascular abnormalities.
Affiliated groups
The following groups have active lines of research with projects that incorporate omics:
- A1G4 – Biomedical research in cancer. IP Enrique Gallardo.
- A1G5 – Molecular and translational research in cancer. IP Maria Rosa Bella.
- A3G6 – Psychoneuroendocrinology and stress in psychosis (PSICPNEC). IP Xavier Labad and Itziar Montalvo
- A4G1 – Obesity and Prader Willi Syndrome. IP Assumpta Caixàs.
- A4G4 – Inflammatory bowel disease, liver disease and Helicobacter pylori. IP Xavier Calvet.
- A5G3 – Intellectual disability and psychiatric disorders of genetic origin. IP Anna Ruiz and Ana Roche.
- A8G1 – Community and health care-related infections study group. IP Oriol Gasch.
- A8G2 – Inflammatory joint disease, bone metabolism and systemic autoimmune diseases. IP Jordi Gratacós and Joan Calvet.
- A8G3 – Translational research in the critically ill patient. co-IPs Josefina López and Oriol Roca.
- A8G4 – Airway inflammation, sleep pathology and ventilation. IP Manel Luján.